The yield on the policy-sensitive two-year Treasury was up 0.03 percentage points at 4.01 per cent following the release of the minutes on Wednesday afternoon, hovering close to hitting its highest ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine.

Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

GlaxoSmithKline agreed on Sept. 17 to settle out of the first Zantac trial in California, which began this month in Oakland. GSK won two defense verdicts in Illinois earlier this year but faced ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...